Alignment Healthcare CEO sells 27,400 shares at $13

Alignment Healthcare’s CEO John E. Kao sold 27,400 indirectly held shares under a Rule 10b5-1 plan while continuing to report substantial direct and indirect ownership.

Rhea-AI Filing Summary

Alignment Healthcare, Inc. (ALHC) reported that Chief Executive Officer and director John E. Kao sold 27,400 shares of common stock on September 14, 2026 at $13.00 per share, in a sale described as a Rule 10b5-1 plan transaction and executed through an indirect holding.

The sold shares were held by the JEK Trust, dated February 8, 2021, for which Mr. Kao serves as trustee; following this transaction, that trust held 590,766 shares indirectly. Separately, Mr. Kao also reported a direct holding of 1,223,473 shares of Alignment Healthcare common stock as of the same date.

Insider Trade Summary 10b5-1

Net Seller: 27,400 shares

Net Sell 2 txns

Insider KAO JOHN E

Role Chief Executive Officer

Sold 27,400 shs ($356K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2	27,400	$13.00	$356K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 590,766 shares (Indirect, See Footnote); Common Stock — 1,223,473 shares (Direct)

Footnotes (2)

1. F1. Date of Rule 10b5-1 plan adoption: 05/27/2026
2. F2. Represents securities held by JEK Trust, dated February 8, 2021, of which Mr. Kao is the trustee.

Key Figures

Shares sold: 27,400 shares Sale price per share: $13.00 per share Indirect shares held after transaction: 590,766 shares +2 more

5 metrics

Shares sold 27,400 shares Common stock sold on September 14, 2026 by John E. Kao (indirectly)

Sale price per share $13.00 per share Price for the 27,400 shares of ALHC common stock sold September 14, 2026

Indirect shares held after transaction 590,766 shares Common stock held indirectly by JEK Trust after the September 14, 2026 sale

Direct shares held 1,223,473 shares Common stock directly held by John E. Kao as of September 14, 2026

Rule 10b5-1 plan adoption date May 27, 2026 Plan under which the September 14, 2026 sale was executed

Key Terms

Rule 10b5-1 plan, indirect ownership, trustee

3 terms

Rule 10b5-1 plan regulatory

"Date of <b>Rule 10b5-1 plan</b> adoption: 05/27/2026"

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

indirect ownership financial

"The sold shares were held by JEK Trust and reported as <b>indirect</b> ownership"

trustee financial

"JEK Trust, dated February 8, 2021, of which Mr. Kao is the <b>trustee</b>"

A trustee is a person or institution legally appointed to hold and manage assets or enforce an agreement on behalf of other people (beneficiaries). Think of a trustee as a neutral referee or custodian who must act in the beneficiaries’ best interests, follow the trust or contract rules, and handle distributions, recordkeeping and enforcement. Investors care because a trustworthy trustee protects their rights, ensures promised payments or remedies are delivered, and can influence recoveries if things go wrong.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ALHC report for CEO John E. Kao?

ALHC reported that John E. Kao sold 27,400 shares of common stock on September 14, 2026 at $13.00 per share. The transaction involved indirectly held shares and is described as occurring under a Rule 10b5-1 trading plan.

At what price were the Alignment Healthcare (ALHC) shares sold by the CEO?

The reported sale by ALHC Chief Executive Officer John E. Kao was executed at $13.00 per share on 27,400 shares of Alignment Healthcare common stock on September 14, 2026, through an indirect holding entity.

Were the ALHC stock sales by John E. Kao under a Rule 10b5-1 plan?

Yes. The filing notes a Rule 10b5-1 plan adoption date of May 27, 2026, and the reported sale of 27,400 shares on September 14, 2026 is identified as occurring under that pre-arranged trading plan.

How many ALHC shares does the JEK Trust hold after the reported sale?

After the transaction, the JEK Trust, for which John E. Kao is trustee, is reported as holding 590,766 shares of Alignment Healthcare common stock indirectly. These trust-held shares were the source of the 27,400-share sale.

What is John E. Kao’s direct ownership in Alignment Healthcare (ALHC) after the transaction?

In addition to the indirectly held trust shares, John E. Kao is reported as directly holding 1,223,473 shares of Alignment Healthcare common stock as of September 14, 2026, according to the holdings information provided.

Is the reported ALHC insider sale an open-market transaction?

The transaction is coded as a sale of common stock in an open market or private transaction, with 27,400 shares sold at $13.00 per share on September 14, 2026, from an indirect holding via the JEK Trust.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/16/2026 - 05:58 PM Accepted by SEC EDGAR 09/16/2026 - 05:57 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

KAO JOHN E

(Last) (First) (Middle)

1100 W. TOWN & COUNTRY RD., SUITE 1600

(Street)

ORANGE CALIFORNIA 92868

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Alignment Healthcare, Inc. [ ALHC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/14/2026		S(1)		27,400	D	$13	590,766	I	See Footnote(2)
Common Stock								1,223,473	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Date of Rule 10b5-1 plan adoption: 05/27/2026

2. Represents securities held by JEK Trust, dated February 8, 2021, of which Mr. Kao is the trustee.

Remarks:

	/s/ Christopher J. Joyce, as Attorney-in-Fact, for John E. Kao	09/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)